compound-G

Compound-G is a novel small molecule growth hormone receptor (GHR) antagonist developed by researchers at Ohio University. It is designed to inhibit the action of growth hormone (GH) by binding to its cognate receptor (GHR), which is frequently overexpressed in pancreatic ductal adenocarcinoma (PDAC). By blocking GHR signaling, compound-G aims to overcome therapy resistance in PDAC by downregulating multidrug efflux transporters (such as ABCB1 and ABCG2), inhibiting epithelial-to-mesenchymal transition (EMT), and promoting apoptosis. In preclinical studies, compound-G has demonstrated the ability to sensitize pancreatic cancer cells and xenograft tumors to chemotherapy, specifically gemcitabine, leading to significant tumor clearance in mouse models. It is being investigated as a potential therapeutic to improve outcomes in pancreatic cancer patients where GHR overexpression correlates with poor prognosis and drug resistance.